Broad Institute prevails in heated dispute over CRISPR patents
By Sharon Begley,
STAT
| 02. 15. 2017
The US patent office ruled on Wednesday that hotly disputed patents on the revolutionary genome-editing technology CRISPR-Cas9 belong to the Broad Institute of Harvard and MIT, dealing a blow to the University of California in its efforts to overturn those patents.
In a one-sentence judgment by the Patent Trial and Appeal Board, the three judges decided that there is “no interference in fact.” In other words, key CRISPR patents awarded to the Broad beginning in 2014 are sufficiently different from patents applied for by UC that they can stand. The judges’ full 51-page decision explaining their reasoning stated that the Broad had persuaded them “that the parties claim patentably distinct subject matter.”
“The Broad landed a knock-out punch,” said Jacob Sherkow of New York Law School, an expert on patent law who has followed the CRISPR case.
The ruling means that, in the eyes of the patent office, breakthrough work by UC biochemist Jennifer Doudna and her colleagues on CRISPR — an ancient bacterial immune system that they repurposed to easily and precisely edit DNA — was not so all-encompassing as to...
Related Articles
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...
By Gina Kolata, The New York Times | 09.22.2025
On May 26, Tracy Atteberry checked in to the hospital at the National Institutes of Health in Bethesda, Md. The 57-year-old has an ultrarare inherited disease that hobbles his immune system so that the most innocuous of germs could kill...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...